关键词：医药；制药公司；医疗保健
摘 要：Asia-Pacific governments continued to focus on cutting the cost of pharmaceutical expenditure over the last six months, as part of an effort to cut overall healthcare costs. Healthcare expenditures rose along with per capita healthcare spending. China’s average per capita healthcare spending grew at higher rate than India and Australia. Leading Asian drugmakers posted a mixed bag of earnings. Takeda Pharmaceutical (TSE: 4502) recorded an increase in net sales, but a decline in net income. Dr. Reddy’s Laboratories (BSE:500124) experienced a large increase in net profit, meanwhile, Mitsubishi Tanabe Pharma (TSE:4508) posted modest sales growth and strong profitability with an increase in net income. Ten out of 11 leading Asian pharmaceutical companies posted positive gains in share prices during the reviewed period, with Ranbaxy’s stock price (BSE: 500359) rising the highest at 27.39%.